News

Biden Administration announces U.S. government procurement of Merck’s investigational antiviral medicine for COVID-19 treatment
June 9, 2021 — The Biden Administration today announced that the U.S. government will procure approximately 1.7 million courses of an investigational antiviral treatment, molnupiravir (MK-4482), for COVID-19 from Merck, pending emergency use authorization (EUA) or approval from the U.S. Food and Drug Administration (FDA).Molnupiravir (MK-4482) is designed to... MORE

Memorandum of Understanding for Acquisition Support Signed Between the Department of Defense and the Department of Health and Human Services
May 26, 2021 — On May 20, 2021, Deputy Secretary of Defense Kathleen Hicks and Deputy Secretary of Health and Human Services (HHS) Andrea Palm signed a memorandum of understanding (MOU) to continue the agencies’ partnership in defeating COVID-19 and preparing for future public health emergencies.The MOU establishes the framework under which the Department of... MORE

Interview with Dr. Kevin Wingerd Chief Technology Officer at the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical)
May 25, 2021 — Excerpt from NCT Magazine's Interview with Dr. Kevin Wingerd, Chief Technology Officer at the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical)... MORE

The COVID-19 Pandemic: Acquisition of Diagnostic Equipment and Testing Assays for COVID-19 Lays the Groundwork for Vaccine and Treatment Success
May 25, 2021 — In early 2020, the world as we knew it began to change. Lockdowns, mask mandates, and travel bans became the new normal as the world fought to slow the spread of the coronavirus (COVID-19).Priorities began to shift, and the development of safe and efficacious vaccines and therapeutics for COVID-19, along with the diagnostic capability needed to... MORE

DOD & HHS Announce DPA Title III Agreement With Retractable Technologies, Inc. to Expand Domestic Production Capacity for Low Dead-Space Safety Syringes and Needles
May 24, 2021 — As part of the national response to COVID-19, the Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), signed an agreement with Retractable Technologies, Inc. (RTI) to expand the production of the low dead-space (LDS) safety syringes and needles. Government funding allocated was $27.3 million.LDS... MORE

Sanofi-GSK report positive interim results for their COVID-19 shot
May 17, 2021 — An experimental COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the French drugmaker said on Monday... MORE

JPM CBRN Medical’s RAIDR RF Innovates DOD Medical Acquisition, Wins BRONZE at 2021 Edison Awards
May 14, 2021 — The annual Edison Awards competition is dedicated to honoring excellence and showcasing game-changing innovations that are rapidly reshaping the evolving world around us. An Edison Award recognition is one of the highest accolades an organization can receive, and the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical... MORE

Using Ultrasound Stimulation to Reduce Inflammation in COVID-19 In-Patients
May 12, 2021 — Researchers at University of California San Diego School of Medicine have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the length of hospital stays... MORE

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
May 10, 2021 — INO-4800 was shown to be safe, well-tolerated and immunogenic in all age groups. Phase 2 results informed INOVIO's selection of 2.0 mg dose for the Phase 3 segment of the trial... MORE

JPEO-CBRND, JPM CBRN Medical Leads DOD Ebola Outbreak Response Efforts
April 28, 2021 — DISCLAIMER: Included references to commercial products does not constitute endorsement by the U.S. Department of Defense or the JPEO-CBRND. The year 2020 will undoubtedly be remembered as the year of the pandemic; the year the world was turned upside down by COVID-19. However, lurking in the shadows and out of the limelight, another viral outbreak... MORE

News Search

JPEO-CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.

JPEO-CBRND Public Affairs Office

The JPEO-CBRND Communications Affairs Network coordinates and responds to all Public Affairs needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.

News Archive - Search by Year and Month

JPEO-CBRND Press Kit

JPEO-CBRND Public Affairs Office